Since the emergence of the Human Immunodeficiency Virus (HIV) in the 1980s, strategies to
combat HIV-AIDS are continuously evolving. Among the many tested targets to tackle this …

We have employed a fragment‐based screen against wild‐type (NL4‐3) HIV protease (PR)
using the Active Sight fragment library and X‐ray crystallography. The experiments reveal …

HIV-1 protease (HIVPR) is an important drug target for combating AIDS. This enzyme is an
aspartyl protease that is functionally active in its dimeric form. Nuclear magnetic resonance …

The flexibility of HIV‐1 protease flaps is known to be essential for the enzymatic activity.
Here we attempt to capture a multitude of conformations of the free and substrate‐bound HIV …

The catalytic conversion ATP+ AMP→ 2ADP by the enzyme adenylate kinase (ADK)
involves the binding of one ATP molecule to the LID domain and one AMP molecule to the …

Revealing the processes of ligand–protein associations deepens our understanding of
molecular recognition and binding kinetics. Hydrogen bonds (H‐bonds) play a crucial role in …

The unliganded form of nitroxide spin-labeled HIV-1 protease and three different complexes
with inhibitors were studied by pulse-EPR spectroscopy to determine “interflap” distance …

Human immunodeficiency virus type 1 protease (HIV‐1 PR) is one of the primary inhibition
targets for chemotherapy of AIDS because of its critical role in the replication cycle of the …

Cyclin-dependent kinases (CDKs) belong to the CMGC subfamily of protein kinases and
play crucial roles in eukaryotic cell division cycle. At least seven different CDKs have been …

Human immunodeficiency virus-1 (HIV-1) protease is an important drug target for acquired
immune deficiency syndrome therapy. Nearly 10 small molecule drugs have been approved …